FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of Adenocarcinoma of the Stomach and Gastroesophageal Junction Expressing HER-2. A Phase II/III Trial of the AIO.
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PETRARCA; PETRARCA/FLOT 6
- 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2018 Planned number of patients changed from 404 to 80.
- 10 Jun 2017 Biomarkers information updated